Volume 90 Issue 6 | p. 17 | Concentrates
Issue Date: February 6, 2012

Sangamo And Shire To Tackle Hemophilia

Department: Business
Keywords: zinc-finger technology, biopharmaceuticals, alliances, hemophilia

Sangamo BioSciences and Ireland’s Shire are collaborating on curative therapies for hemophilia and other monogenic diseases. They will use Sangamo’s zinc finger DNA-binding protein (ZFP) technology for gene editing. To get exclusive worldwide rights to ZFPs targeting four genes—for blood clotting factors VII, VIII, IX, and X—Shire will pay Sangamo $13 million up front, as well as future milestones and royalties. Sangamo will handle R&D up to the clinical-trial stage, . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society